国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (5): 332-335.doi: 10.3760/cma.j.issn.1673422X.2017.05.003

• 论著 • 上一篇    下一篇

Smad4、雌激素受体表达与乳腺癌临床病理特征的相关性

陈国平,李京泰,夏立平,郑武平,范平明,陈峙霖,吕鹏飞,苏洁之   

  1. 570102 海口，海南医学院第一附属医院乳腺胸部肿瘤外科
  • 出版日期:2017-05-08 发布日期:2017-04-19
  • 通讯作者: 李京泰，Email: ljt202020@163.com E-mail:ljt202020@163.com

Correlations between the expressions of Smad4, estrogen receptor and the clinicopathological features of breast cancer

Chen Guoping, Li Jingtai, Xia Liping, Zheng Wuping, Fan Pingming, Chen Zhilin, Lyu Pengfei, Su Jiezhi   

  1. 570102 海口，海南医学院第一附属医院乳腺胸部肿瘤外科
  • Online:2017-05-08 Published:2017-04-19
  • Contact: Li Jingtai E-mail:ljt202020@163.com

PDF

686

摘要： 目的探讨Smad4和雌激素受体（ER）在乳腺癌中的表达及其与乳腺癌临床病理特征之间的关系，以及二者的相关性。方法应用免疫组织化学SP法检测50例浸润性乳腺癌、12例原位癌及15例正常乳腺组织中Smad4和ER的表达，分析二者在不同的临床分期、分化程度及淋巴结转移中的表达差异，探讨二者的相关性。结果Smad4在浸润性乳腺癌和正常乳腺组织中的阳性表达率为分别为52.00%、93.33%，差异有统计学意义（χ2=8.329，P=0.004），ER阳性表达率分别为60.00%、40.00%，差异无统计学意义(χ2=1.868，P=0.172)。原位癌与浸润性乳腺癌比较，Smad4阳性表达率分别为75.00%和52.00%，差异无统计学意义（χ2=2.082，P=0.149），ER阳性表达率表达分别为58.33%、60.00%，差异无统计学意义（χ2=0.011，P=0.916）。Smad4表达与乳腺癌TNM分期（χ2=6.392，P=0.011）和淋巴结转移（χ2=6.738，P=0.009）有关，与组织学分级（χ2=0.542，P=0.462）无关。ER表达与乳腺癌淋巴结转移（χ2=4.133，P=0.042）和组织学分级（χ2=5.357，P=0.021）有关，与TNM分期（χ2=1.159，P=0.282）无关。Smad4蛋白与ER在乳腺癌组织中的表达呈正相关（r=0.263，P=0.032）。结论Smad4在乳腺癌中表达低于正常组织，Smad4与ER的表达与乳腺癌不同的临床病理特征之间具有一定的相关性，且二者表达呈正相关。

关键词: 乳腺肿瘤, 受体, 雌激素, Smad4蛋白质

Abstract: ObjectiveTo explore the expressions of Smad4 and estrogen receptor (ER) and their interrelation, and the relationship with the clinicopathological features of breast cancer. MethodsThe immunohistochemical SP method was used to detect the expressions of Smad4 and ER in 50 case of invasive cancer, 12 cases of carcinoma in situ and 15 cases of normal breast tissues. The differences in different clinical stages, differentiation degrees and nodal metastases were analyzed. The correlation between Smad4 and ER was explored. ResultsThe positive expression rate of Smad4 in invasive cancer was 52.00%, which lower than that in normal breast tissue (93.33%), with a significant difference (χ2=8.329, P=0.004), positive expression rates of ER were 60.00% and 40.00% respectively, with no significant difference (χ2=1.868, P=0.172). The positive expression rates of Smad4 in carcinoma in situ and invasive cancer were 75.00% and 52.00% respectively, with no significant difference (χ2=2.082, P=0.149). The positive expression rates of ER were 58.33% and 60.00% respectively, with no significant difference (χ2=0.011, P=0.916). The positive expression of Smad4 was related to the TNM stage (χ2=6.392, P=0.011) and the lymph node metastasis(χ2=6.738, P=0.009), but it was not associated with the histologic grade (χ2=0.542, P=0.462). The positive expression of ER was related to the lymph node metastasis (χ2=4.133, P=0.042) and histologic grade (χ2=5.357, P=0.021), but it was not associated with the TNM stage (χ2=1.159, P=0.282). There was positive correlation between Smad4 and ER in breast cancer tissue (r=0.263，P=0.032). ConclusionSmad4 is expressed at lower level  in breast cancer than in normal breast tissue. The expressions of Smad4 and ER are related to the different clinicopathological features of breast cancer with positive correlation

Key words: Breast neoplasms, Receptors, estrogen, Smad4 protein